Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2018-09-14 Legal Proceedings Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study
Legal Proceedings Report Classification · 99% confidence The document is titled with a clear announcement: "Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study." It details clinical trial results, manufacturing updates, and provides contact information, all characteristic of a press release announcing significant operational and clinical milestones. The presence of the header "Regulated information" further confirms its nature as a formal corporate disclosure. Since it is a comprehensive announcement of results and strategic updates, it is best classified as an Earnings Release (ER) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and content focus on results, ER is the closest fit among the options for a major periodic update, although it is not strictly quarterly earnings. However, looking closely at the definitions, this is a clinical/operational update, not a standard financial earnings report. It is a press release announcing key operational and clinical data. Since there isn't a specific 'Clinical Trial Result Announcement' code, we must choose the best fit. It is not a full Annual Report (10-K), Interim Report (IR), or a Call Transcript (CT). It is a detailed announcement of results, which often overlaps with the function of an Earnings Release (ER) which covers period results/highlights. Given the detailed nature of the results and manufacturing updates, it functions as a major corporate update. If we consider the closest fit for a major, non-financial-period-specific announcement detailing significant progress, ER (Earnings Release - initial announcement of periodical financial results/highlights) is often used broadly for major operational announcements in some databases, but this is primarily clinical data. Since it is a detailed press release announcing significant progress, and not a short announcement of a report (RPA/RNS), it is most likely intended to be classified as a general corporate update. Given the options, and recognizing it's a press release detailing key operational achievements, ER is the most plausible category for a major non-financial results announcement, or potentially IP if it were a presentation deck, but it reads like a press release. Given the context of financial reporting databases, major operational/clinical updates are often grouped near ERs. However, since it is a detailed press release announcing clinical results and manufacturing progress, and not a standard financial earnings report, it is a strong candidate for a general Regulatory Filing (RNS) if no better fit exists. Let's re-evaluate: It is a detailed press release announcing clinical trial results and manufacturing optimization. This is a significant corporate event announcement. It is not a short announcement of a report (RPA/RNS). It is not a standard financial report (10-K, IR). It is not a presentation (IP). It is most closely aligned with the function of an Earnings Release (ER) in conveying key period performance highlights, even if the performance metric here is clinical success rather than revenue/profit. Given the lack of a specific clinical trial result code, ER is chosen as the best fit for a major, structured announcement of performance metrics, followed closely by RNS as a fallback. I will select ER as it details 'results' and progress, similar to how an ER details financial results and progress. Confidence is moderate due to the clinical focus.
2018-09-14 English
Bone Therapeutics annonce les résultats finaux de l’étude de Phase I/IIA avec ALLOB dans les fractures avec retard de consolidation
Regulatory Filings Classification · 92% confidence The document is a press release from Bone Therapeutics dated September 14, 2018, announcing the final positive results of a Phase I/IIA clinical study for their product ALLOB in treating non-union fractures. It details clinical outcomes, safety profiles, and significant updates regarding an optimized manufacturing process intended for future commercialization. This content—announcing specific clinical trial results and operational updates (like manufacturing improvements) that precede a full regulatory filing or annual report—is characteristic of an Earnings Release (ER) or a general press release detailing operational milestones. Since it focuses heavily on the *results* of a clinical trial and operational progress rather than just summarizing quarterly financials (ER) or being a transcript (CT), it fits best as a general announcement of significant operational/clinical progress. However, given the options, the detailed announcement of clinical trial results and operational progress, which often accompanies or precedes formal financial reporting periods, aligns most closely with an Earnings Release (ER) if it were quarterly, or a general Regulatory Filing (RNS) if it doesn't fit elsewhere. Since it is a detailed announcement of clinical trial success and manufacturing strategy, which is a major business update, and not a formal financial statement, it is best classified as a general announcement. Given the options, and since it is a detailed announcement of clinical/operational progress rather than a formal financial summary (ER) or a short notice (RPA), RNS is the most appropriate fallback for a significant, non-standardized corporate announcement, although it contains elements of an Investor Presentation (IP) in its detail. Given the context of clinical trial results and manufacturing updates, it is a significant corporate announcement, making RNS the safest general classification if ER (which usually implies financial results) is not a perfect fit, or IP if it were a slide deck. Since it is a press release detailing results, RNS is the most suitable general regulatory announcement category.
2018-09-14 French
PR_2018-09-03_BT_CB Denominator_EN_Final.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information on the total number of voting rights and shares" and explicitly states it is publishing this information in accordance with Article 15 of the Belgian Law regarding the publication of major shareholdings. It details changes in the total number of shares, voting rights, convertible bonds, and warrants. This content directly relates to changes in the company's capital structure and ownership disclosure, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports the resulting denominator after a capital event (conversion of bonds). While it touches upon shareholding changes, the primary focus is the calculation of the new total share count following a financing/conversion event. It is not a general regulatory filing (RNS) because it fits a more specific category (SHA).
2018-09-03 English
PR_2018-09-03_BT_CB Denominator_FR_Final.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions" (Information relating to the total number of voting rights and shares) and is dated September 3, 2018. It explicitly details the increase in the total number of shares and voting rights following the conversion of convertible bonds, citing compliance with Belgian law regarding significant shareholdings. This content directly relates to changes in the company's capital structure and share count, which aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA).
2018-09-03 French
PR_2018-08-30_BT_2018H1_EN_Final.pdf
Interim / Quarterly Report Classification · 95% confidence The document is an official announcement of H1 2018 financial results for Bone Therapeutics. It contains key highlights, operational updates, and condensed financial statements (Statement of Comprehensive Income and Statement of Financial Position). While it references a full interim report available on the website, the document itself provides substantive financial data and analysis for the six-month period, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-08-30 English
CP_2018-08-30_BT_2018H1_FR_Final.pdf
Earnings Release Classification · 99% confidence The document explicitly announces the publication of financial results for the first half of 2018 ("Bone Therapeutics publie ses résultats du premier semestre 2018"). It contains key financial figures, operational highlights for the period, and forward-looking statements, which are characteristic of an Earnings Release (ER). However, it also mentions that the full report is prepared according to IFRS and refers the reader to the 'Rapport semestriel' (Interim Report) for detailed notes (Note 5). The document structure strongly resembles a press release summarizing results, often issued concurrently with or just before the full interim report. Given the content focuses on summarizing the period's performance and includes a conference call announcement, it fits the definition of an Earnings Release (ER). If the document were the full, detailed financial statement, it would be classified as an Interim Report (IR). Since this is the announcement/summary of those results, ER is the most appropriate code, although IR is closely related. The length (over 32k characters) suggests it is more than just a brief announcement, but the format is clearly that of a press release accompanying the results. H1 2018
2018-08-30 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.